CoreRx continues to grow in 2010, providing unsurpassed contract pharmaceutical development services to the pharma & biotech industries. This is more evident with the latest announcement of the Tampa Bay Business Journal announcement of the Fast 50 nominees. http://www.bizjournals.com/tampabay/stories/2010/06/14/daily4.html
Posts Tagged ‘CoreRx’
CoreRx Continues Expansion – Seeks Top Pharmaceutical Development Candidates
Thursday, April 15th, 2010Pharmaceutical development provider CoreRx announced today it will be hiring top candidates in the areas of preformulation and formulation development. CoreRx will also increase headcount in analytical, manufacturing and client logistics, strengthening their commitment to customer first service excellence.
“It is easy to stay committed to client timelines and project quality when there is no turnover and controlled organic growth,” Daviau said. “Because we offer benefits and a nurturing environment that rewards commitment to quality and innovation, we find ourselves in a position to bring more outstanding candidates into the fold.”
Unlike other CROs replacing headcount from attrition or layoffs, CoreRx has not lost a single employee in their existence. The company has not been a part of the large-scale layoffs which have dominated the pharmaceutical industry in recent months, and that put CoreRx in a better position as the recovery takes root.
Posted in CoreRx News |
CoreRx, Inc. and SoluBest, Ltd. Announce Collaborative License Agreement for Solumer™ Technology
Wednesday, February 3rd, 2010SoluBest, Ltd, today announced an agreement to license its proprietary nanotechnology platform for significantly improving the bio-performance of poorly soluble and insoluble drugs to CoreRx, Inc., an innovative contract formulation company. SoluBest’s Solumer™ technology is extremely versatile, as it can be applied to a wide range of pharmaceuticals. The license agreement will provide CoreRx with access to Solumer™ technology and the rights to apply the technology to client’s drug candidates currently in clinical development.
“We are excited at the opportunity to enhance our contract drug development offerings through the Solumer™ technology,” said Todd R. Daviau, CEO of CoreRx. “Since the beginning, CoreRx has been working to meet the increasing formulation development challenges of drug delivery, as well as performance enhancement of our client’s drug products. As companies continue to outsource development, speed, quality, and innovation become increasingly important to our contract lab offerings. (more…)
Posted in CoreRx News, Formulation Development |